| | | | | | Mass-Spectrometry as an Unbiased Tool to Discover, Identify and Quantify Protein Biomarkers | | | | Dear Subscriber,
With 2019 already in full swing, we want to first wrap up 2018 by highlighting two DIA related news: our collaboration with PharmaFluidics and the absolute quantification with our new PQ500™ plasma kit. Then, going back to the future, we will provide you with an outlook for the upcoming conference season and software releases.
COMBINING DIA WITH MICRO-PILLAR ARRAY COLUMNS TO INCREASE PRECISION AND SENSITIVITY
Data-independent acquisition (DIA) has been introduced as a novel data acquisition strategy to combine the high-throughput advantages of data-dependent acquisition (DDA) with the high reproducibility of a targeted analysis such as parallel reaction monitoring (PRM). To fully benefit from the technological advantages of DIA, a maximum number of separated peaks is required from liquid chromatography, referred to as peak capacity. In normal packed chromatography columns, peak capacity is limited by the maximum length of the column and the maximum pressure that can be applied to the system.
More importantly, peak capacity flattens despite increasing gradient lengths, usually around 3-4 hours. In order to push the detection and quantification limits, Biognosys teamed up with PharmaFluidics and applied their micro-pillar array columns (µPAC™) in a DIA experiment using HeLa cell digest. By using µPAC, Biognosys was able to increase the overall peak capacity at any gradient length. In addition, the peak capacity scaled with increasing gradient length. This enabled Biognosys to detect and quantify on average more than 9’000 proteins per run at a gradient length of 6 hours, which represents the current highest efficiency. If you are interested in reading the complete tech note or viewing the webinar recording, please follow the links below.
| | | | | |
UNBIASED AND ABSOLUTE QUANTIFICATION OF MORE THAN 500 PLASMA PROTEINS IN PANCREATIC CANCERRecent studies have demonstrated the value of quantifying circulating proteins for early disease detection, prediction of therapeutic response, and treatment monitoring. Although the utility is clear, standardization of measurement methods for a large number of proteins from plasma remains challenging. In one of our most recent studies, we investigated plasma proteins using DIA mass spectrometry in samples from normal and pancreatic cancer subjects. The data was analyzed and absolutely quantified using Biognosys’ PQ500™ reference panel; constructed of 800 stable-isotope standard (SIS) peptides spanning more than 500 proteins. With our approach, we could effectively identify dysregulated proteins that are known biomarkers for pancreatic cancer. If you would like to know more about our biomarker discovery approach, please contact us at services@biognosys.com or meet us at one of the upcoming conferences.
SPECTRODIVE™ 9.0 AND QUIC™ 3.0 TO BE LAUNCHED AT EUPA AND ABRF
Targeted proteomics is a powerful, unbiased analysis methodology that combines the precision quantification known from biological methods like ELISA with high multiplexing capabilities. SpectroDive is Biognosys' data analysis software for targeted proteomics, and we are excited to unveil our new SpectroDive 9.0 at the upcoming EUPA conference. Join us in Potsdam (Berlin) to explore its new features. Are you more concerned about the performance of your mass spectrometry instrumentation? QuiC is Biognosys' performance monitoring and quality control software that minimizes instrument downtime and troubleshooting requirements through real-time monitoring of a multitude of critical performance parameters. For 2019, we also gave QuiC a significant upgrade, which will be presented at the upcoming ABRF conference. Join us in San Antonio, TX to learn more about QuiC 3.0.
MEET OUR TEAM AT THE FOLLOWING CONFERENCES AND EVENTS
ESMO Targeted Anticancer Therapies February 25-28, 2019, Paris, France
ASCO-SITC Clinical Immuno-Oncology Symposium February 28-March 2, 2019, San Francisco, CA, USA Keystone Symposium on Phenotypic Drug Discovery March 3-7, 2019, Breckenridge, CO
ABRF March 23-26, 2019, San Antonio, TX, USA
EUPA Proteomics Forum, March 24-28, 2019, Potsdam, Germany
AACR Annual Meeting March 29-April 2, 2019, Atlanta, GA, USA
MSACL - Mass Spectrometry: Applications to the Clinical Lab March 31-April 4, 2019, Palm Springs, CA, USA
Keystone Symposium on Proteomics and its Application to Translational and Precision Medicine April 7-11, 2019, Stockholm, Sweden
ASGCT Annual Meeting April 29-May 2, 2019, Washington DC, USA
SPS Annual Swiss Proteomics Meeting May 23-24, 2019, Montreux, Switzerland
ASMS 2019 Annual Conference June 2-6, Atlanta, GA, USA
Best regards,
The Biognosys Team
| | | | | | | | | | | | | | | | | | | |
